SCHEMBL10004100

SCHEMBL10004100

Cc1nc2c(c(OCC(F)(F)F)c(C(=O)O)n2C)c(=O)n1Cc1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.44
▸ KDM4E B2RXH2 5/20 0.44
▸ HSD17B10 Q99714 3/20 0.44
▸ TSHR P16473 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ SMN1; SMN2 Q16637 5/20 0.42
▸ LMNA P02545 5/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HDAC3 O15379 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10004766 0.93 NPSR1 (0.42) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL10004150 0.93 NPSR1 (0.44) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL10004584 0.91 BLM (0.48) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL10004555 0.90 KMT2A (0.49) ALDH1A1KDM4EHSD17B10TSHRHPGD
SCHEMBL10004316 0.90 KDM4E (0.52) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL10004560 0.87 TDP1 (0.48) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL10003653 0.85 KMT2A (0.47) ALDH1A1KDM4EHSD17B10LMNAHPGD
SCHEMBL10004065 0.84 KMT2A (0.43) ALDH1A1KDM4EHSD17B10TSHRCYP1A2
SCHEMBL10004914 0.84 MAPT (0.45) ALDH1A1KDM4EHSD17B10TSHRUSP2
SCHEMBL10004728 0.84 ALDH1A1 (0.45) ALDH1A1HSD17B10TSHRUSP2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471793-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-10-05 — — EP disclosed
US-8614208-B2 Fused heterocyclic ring derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-12-24 — — US disclosed
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 — — US disclosed
EP-2471793-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ALDH1A1 321/4885KDM4E 405/4885HSD17B10 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback